Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYGL | P06737 | 1/20 | 0.47 |
| ▸ | CDK1 | P06493 | 1/20 | 0.40 |
| ▸ | GRIN1 | Q05586 | 5/20 | 0.39 |
| ▸ | GRIN2B | Q13224 | 5/20 | 0.39 |
| ▸ | PCNA | P12004 | 1/20 | 0.39 |
| ▸ | ACSS2 | Q9NR19 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.38 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.38 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.38 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.38 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30791548 | 0.83 | PYGL (0.65) | PYGLGRIN1GRIN2BPDPK1TRPV1 | |
| SCHEMBL28190396 | 0.83 | PYGL (0.65) | PYGLGRIN1GRIN2BPDPK1TRPV1 | |
| SCHEMBL27836800 | 0.82 | PTPN1 (0.43) | PYGLCDK1 | |
| SCHEMBL91334 | 0.79 | PYGL (0.49) | PYGLGRIN1GRIN2BPCNAACSS2 | |
| SCHEMBL1750889 | 0.78 | PYGL (0.48) | PYGLGRIN1GRIN2BPCNAKMT2A | |
| SCHEMBL1751947 | 0.77 | LMNA (0.55) | ALDH1A1 | |
| SCHEMBL78415 | 0.77 | GAA (0.48) | PYGLGRIN1GRIN2BKMT2ATRPV1 | |
| SCHEMBL1246997 | 0.76 | CDK1 (0.47) | CDK1TRPV1ALDH1A1 | |
| SCHEMBL30729428 | 0.75 | ALDH1A1 (0.48) | PYGLGRIN1GRIN2BKMT2ATRPV1 | |
| SCHEMBL14387746 | 0.75 | HDAC1 (0.53) | PCNAHSD17B1HSD17B2FFAR1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7968720-B2 | Secondary amines as renin inhibitors | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-06-28 | — | — | US | disclosed |
| US-20090176823-A1 | Secondary Amines as Renin Inhibitors | ACTELION PHARMACEUTICALS LTD. (CH) | 2009-07-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090176823-A1 | Secondary Amines as Renin Inhibitors | REN, ACE, AGTR1 | PYGL 1064/4885CDK1 853/4885GRIN1 1446/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.